Availability of Alpha-Emitting Radioisotopes by Reactor and Accelerator Production and via Decay of Naturally Occurring Parents
Because of the high LET, interest in the use of alpha-emitting radioisotopes for targeted therapy has rapidly increased over the last decade. A variety of candidates are available from decay of naturally occurring species such as 229Th and also via both accelerator and reactor production routes (Chaps. 5 and 6). The chemistry required for separation and purification of these actinide species is complex and requires multi-step sequential procedures. Therapeutic applications of alpha-emitting radioisotopes primary focus on oncology and include tumor therapy and palliation of skeletal metastases. The radiopharmaceuticals which have been prepared with alpha emitters and the highlights of preclinical studies and status of clinical applications are discussed in subsequent chapters. This chapter is focused on the production and process chemistry required to provide these alpha emitters for subsequent radiolabeling and biological evaluation.
KeywordsAlpha Emitter Titanium Phosphate Chlorinate Cobalt Dicarbollide Daughter Radionuclide High Flux Isotope Reactor
- Atcher RW, Firedman AM, Hines J. Isotopic generator for bismuth-212 and lead-212 from radium, US Patent 4,663,129, May 5, 1987.Google Scholar
- Boll RA, Mirzadeh S, Kennel SJ. Optimization of radiolabeling of immunoproteins with 225Bi. Radiochimica Acta. 1997,79:145–9.Google Scholar
- Firestone RB, Eksrom LP. Radioactive elements, version 2.1. LBNL, USA. http://ie.lbl.gov/toi/index.asp; 2004.
- Geerlings MW, Kaspersen FM, Apostolidis C, et al. The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun. 1993;14:121–5.Google Scholar
- Mirzadeh S, Garland MA. US Patent 7,852,975 B2, issued Dec. 14, 2010. Production of thorium-229 using helium nuclei.Google Scholar
- Morgenstern A, Apostolidis C, Bruchertseifer F, et al. Cross-section of the reaction 232Th(p,3n)230Pa for production of 230U for targeted alpha therapy. Appl Radiat Isot. 2008a;66(10):1275–80.Google Scholar
- Morgernstern A, Lebeda O, Strusa J, et al. Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa. Anal Chem. 2008b;80(22):8763–70.Google Scholar
- Shishkin DN, Krupitskii SV, Kuznetsov SA. Extraction generator of 223Ra for nuclear medicine. Radiokhimiya. 2011;53(4):343–5.Google Scholar
- Van Geel JNC, Fuger JJ, Koch L. Method for producing actinium-225 and bismuth-213. United States Patent 5355394; 1994.Google Scholar